US FDA approves Syndax's blood cancer drug
Nov 15 (Reuters) -The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' SNDX.O drug for the treatment of adult and pediatric patients with a type of blood cancer, sending the company's shares up 3% in after-hours trading.
The drug revumenib, sold under the brand name Revuforj, is used to treat acute leukemia with a KMT2A translocation, which are chromosomal rearrangements that involve the KMT2A gene and are found in about 10% of acute leukemia patients.
Revuforj belongs to a new class of drugs called menin inhibitors which prevent the binding of a protein called menin to another protein called MLL, which stops the activation of proteins that can cause cancer cells to grow.
The approval was based on an early- to mid-stage trial with 104 patients, where the drug showed 21% complete remission with a partial recovery in the levels of specific blood cells.
Leukemia affects more than 60,000 people in the United States annually, according to the National Institutes of Health.
This is the second FDA nod for Syndax this year after the agency approved the company and partner Incyte's INCY.O drug Niktimvo in August for patients with chronic graft-versus-host disease, a potentially fatal immune reaction that could occur after a stem cell transplant.
Syndax expects that the 110 mg and 160 mg tablets of Revuforj will be available for order in the United States this month.
Reporting by Christy Santhosh in Bengaluru; Editing by Maju Samuel
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
